THOUSAND OAKS, Calif. – The 11 directors of Amgen Inc. (Nasdaq: AMGN) were re-elected at the annual meeting held at Four Seasons Hotel Westlake Village, Calif., the company said last night.
About 86.9 percent of outstanding shares were represented at the meeting, Amgen said.
ADVERTISEMENT
ADVERTISEMENT
Returned to the board of directors were David Baltimore, Frank J. Biondi Jr., Jerry D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer, Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, Leonard D. Schaeffer and Kevin W. Sharer. Each received at least 87.7 percent of the votes cast, Amgen said.
Shareholders also ratified Ernst & Young as Amgen’s independent registered public accountants for the year ending Dec. 31, 2008, by about 97.6 percent of votes cast.
A non-binding resolution recommending that the company eliminate the supermajority voting requirements in its bylaws and certificate of incorporation was favored by about 78.7 percent, while a proposal relating to animal welfare received less than 4.9 percent of votes, Amgen said.
The final tallies will be included in the company’s next quarterly report to the U.S. Securities and Exchange Commission.
Amgen Inc. (Nasdaq: AMGN) – based in Thousand Oaks, Calif., with operations in 10 other U.S. locations, including West Greenwich – is a biotechnology company focusing on the development and production of new medicines for human use. Additional information is available at www.amgen.com.
Hattie Bryant invites you to
watch a one- to four-minute video tip each day about best business practices from
the weekly television show, Small Business School.
